# United States Orthoptics Burden and Treatment Funnel

## Bottom line

The best-supported national picture is this: the conditions most squarely in orthoptics’ lane are common enough to matter at population scale, but the United States still lacks a single linked national dataset that follows children from screening through referral, diagnosis, treatment, adherence, and resolution. For preschool children, population-based U.S. studies put **manifest strabismus at roughly 2.5% to 2.6%** and **amblyopia generally around 1.8% to 2.6% depending on cohort and ethnicity**; in today’s population, that translates to **roughly half a million preschool-age children with strabismus** and **roughly 0.4 to 0.6 million with amblyopia**, even before counting the larger pool with amblyogenic refractive risk factors. Claims-based data suggest that among all U.S. children under 18 with commercial insurance, **3.2% carry a strabismus diagnosis** and **1.5% carry an amblyopia diagnosis**, which implies about **2.35 million diagnosed pediatric strabismus cases** and **1.10 million diagnosed pediatric amblyopia cases** if those rates were applied to the full U.S. child population. citeturn25search3turn25search9turn31view3turn22search1turn23search2turn24search8

The screening-to-care pathway is where the system leaks. The USPSTF still recommends at least one vision screening for all children ages 3 to 5 years, yet it also noted that **screening rates at age 3 are only about 40%**. In the 2021 National Survey of Children’s Health, **61% of school-age children had a screening within the prior 2 years**; **30% of those screened were referred**, and **92% of those referred reportedly established specialty care**. That means only about **16.8% of all school-age children** made it from “screened” to “referred and seen,” using that particular pathway definition. In preschool follow-up studies, **community-based follow-up after failed screening has often sat around 59%**, with modeled ranges around **50.5% to 63.8%**, and reviews still describe follow-up failure as a major bottleneck. citeturn27search17turn12search15turn18search2turn16search0turn16search1turn16search3

The clinical upside is that once children are actually diagnosed and treated early, outcomes are often good. PEDIG trials found that for moderate amblyopia in children younger than 7 years, **atropine and patching produced similar improvement by 6 months**; in children **7 to <13 years**, **53% responded** to active treatment versus **25%** to optical correction alone; and for symptomatic childhood convergence insufficiency, **office-based vergence/accommodative therapy with home reinforcement** produced a **73% successful-or-improved rate at 12 weeks**, with **87.5%** of those successful/improved children still doing well one year later. But the pathway does not end there: amblyopia recurrence after successful treatment remains substantial at about **25% within the first year** in classic PEDIG-era evidence. citeturn10search8turn10search1turn33search1turn10search3turn11search6

## Stat cards

Citations in the **Source** column are the clickable source links.

| Value | Metric / what it measures | Scope & population | Period | Source | Confidence | One-line so what |
|---|---|---|---|---|---|---|
| **2.5%** | Manifest strabismus prevalence | Preschool children ages 6–72 months in the Multi-Ethnic Pediatric Eye Disease Study; African American and Hispanic children in Los Angeles County | Study years 2003–2007; article 2008 | Varma et al., *Ophthalmology* 2008; summarized in PubMed and follow-on references citeturn31search8turn25search6 | **[Measured]** | Roughly 1 in 40 preschoolers had manifest misalignment in a large U.S. population-based cohort. |
| **2.6%** | Strabismus prevalence | Preschool children ages 6–71 months in the Baltimore Pediatric Eye Disease Study | Article 2009 | Friedman et al., *Ophthalmology* 2009, cited in BPEDS article citeturn31view3 | **[Measured]** | A second U.S. population-based cohort lands in nearly the same range, which increases confidence that preschool strabismus burden is genuinely population-scale. |
| **≈ 557,964 children** | Estimated number of preschool children with strabismus today | U.S. children ages 0–5, using 2.5% prevalence × estimated 22.32 million children ages 0–5 | 2025 population denominator | Author calculation from Census 2025 total population and age shares, plus MEPEDS prevalence citeturn23search2turn24search8turn31search8 | **[Estimate]** | Even conservative prevalence implies well over half a million preschoolers in today’s U.S. may have strabismus. |
| **677,000 cases** | National projected count of manifest strabismus | U.S. children ages 6–71 months | Using then-current national population projections in BPEDS article | Friedman et al., *Ophthalmology* 2009 PubMed summary citeturn25search3 | **[Estimate]** | The older study-level national extrapolation is in the same ballpark as the 2025 back-of-envelope update above. |
| **1.81%** | Amblyopia prevalence | Asian and non-Hispanic White preschool children | Article 2013 | McKean-Cowdin et al., *Ophthalmology* 2013 citeturn25search9 | **[Measured]** | Preschool amblyopia was under 2% in this U.S. population-based cohort, but still translates to many affected children nationally. |
| **2.6%** | Amblyopia prevalence | Hispanic/Latino preschool children in MEPEDS | Article 2008 | Varma et al., *Ophthalmology* 2008 PubMed summary citeturn26search11 | **[Measured]** | Hispanic preschoolers in MEPEDS sat at the high end of the U.S. population-based amblyopia estimates. |
| **78%** | Share of amblyopia attributable to refractive error | Hispanic/Latino preschool children with amblyopia in MEPEDS | Article 2008 | Varma et al., *Ophthalmology* 2008 PubMed summary citeturn26search11 | **[Measured]** | The dominant mechanism was refractive, which is exactly why orthoptic care intersects so heavily with early screening and spectacle management. |
| **< 2%** | Amblyopia prevalence | White and African American preschool children ages 6–71 months in BPEDS | Article 2009 | Friedman et al., *Ophthalmology* 2009 PubMed summary citeturn26search5 | **[Measured]** | Amblyopia is a little less common than strabismus in preschool cohorts, but still plainly not rare. |
| **≈ 401,734 to 580,282 children** | Estimated number of preschool children with amblyopia today | U.S. children ages 0–5, using 1.8% to 2.6% prevalence × estimated 22.32 million children ages 0–5 | 2025 population denominator | Author calculation from Census 2025 population and population-based preschool prevalence studies citeturn23search2turn24search8turn25search9turn26search11 | **[Estimate]** | The plausible national preschool amblyopia burden is in the high six figures. |
| **271,000 cases** | National projected count of amblyopia | U.S. children ages 30–71 months | Using then-current national population projections in BPEDS article | Friedman et al., *Ophthalmology* 2009 PubMed summary citeturn25search3 | **[Estimate]** | The older extrapolation is lower than a 2025 update partly because the denominator here is narrower and the population was smaller. |
| **1% to 6%** | Prevalence range for anisometropia, amblyopia, and strabismus | Recent U.S. population-based studies in children under 6, summarized by USPSTF evidence review | Review published 2017 | Jonas et al., USPSTF evidence review / NCBI Bookshelf citeturn34search0turn34search6 | **[Measured]** | Nationally representative anisometropia-alone numbers are thin; the USPSTF evidence synthesis is the safest summary figure. |
| **5.0%** | Amblyopia risk factor prevalence on photoscreening | Preschool children in 16 U.S. photoscreening programs, >400,000 participants | Review published 2017 | USPSTF evidence review / NCBI Bookshelf citeturn34search0turn34search6 | **[Measured]** | The pool at risk is much larger than the pool with established amblyopia. |
| **≈ 1.12 million children** | Estimated number of preschoolers with amblyopia risk factors today | U.S. children ages 0–5, using 5.0% × estimated 22.32 million ages 0–5 | 2025 population denominator | Author calculation from Census 2025 population and USPSTF evidence review citeturn23search2turn24search8turn34search0 | **[Estimate]** | This is the broad upstream population orthoptics-related systems are trying to catch before permanent vision loss sets in. |
| **5.1%** | Children who would have benefited from spectacle correction under prescribing guidelines | Preschool children in BPEDS | Article 2009 | Giordano et al., *Ophthalmology* 2009, as summarized in university repository/search snippet citeturn7search10turn7search22 | **[Measured]** | Clinically meaningful refractive error burden in preschoolers is large even before amblyopia is diagnosed. |
| **1.3%** | Already prescribed correction | Same BPEDS preschool cohort | Article 2009 | Giordano et al., *Ophthalmology* 2009 summary citeturn7search10turn7search22 | **[Measured]** | The gap between “needed glasses” and “already had glasses” was about fourfold in that cohort. |
| **6.7%** | Prevalence of any significant eye diagnosis | U.S. children ≤19 years in commercial insurance claims | 2010–2018 claims window; article 2021/2022 | Pineles et al., *Ophthalmic Epidemiology* citeturn22search1turn22search2 | **[Measured]** | Claims-based diagnosed disease burden is much higher than the narrower preschool amblyopia/strabismus prevalence figures because it spans all pediatric eye disease and all childhood ages. |
| **3.2%** | Diagnosed strabismus prevalence | U.S. commercially insured children ≤19 years | 2010–2018 claims window | Pineles et al., *Ophthalmic Epidemiology* citeturn22search1turn22search2 | **[Measured]** | In real-world pediatric claims, strabismus is the single most common diagnosed major eye disease. |
| **≈ 2.35 million children** | Estimated number of children with diagnosed strabismus if 3.2% applied to all U.S. children <18 | U.S. children under 18, 73.48 million denominator | 2025 denominator + claims prevalence | Author calculation from Census 2025 and OptumLabs prevalence citeturn23search2turn22search1 | **[Estimate]** | Even acknowledging claims under- and over-capture issues, the diagnosed pediatric strabismus population is probably in the millions, not the hundreds of thousands. |
| **1.5%** | Diagnosed amblyopia prevalence | U.S. commercially insured children ≤19 years | 2010–2018 claims window | Pineles et al., *Ophthalmic Epidemiology* citeturn22search1turn22search2 | **[Measured]** | Claims-based diagnosed amblyopia is somewhat lower than risk-factor prevalence, which is exactly what you would expect in a funnel with attrition. |
| **≈ 1.10 million children** | Estimated number of children with diagnosed amblyopia if 1.5% applied to all U.S. children <18 | U.S. children under 18, 73.48 million denominator | 2025 denominator + claims prevalence | Author calculation from Census 2025 and OptumLabs prevalence citeturn23search2turn22search1 | **[Estimate]** | The diagnosed amblyopia caseload implied by national child population size remains very large. |
| **6.9% vs 5.6% vs 5.9%** | Any significant eye diagnosis by race/ethnicity | White vs Black vs Hispanic children in OptumLabs claims | 2010–2018 claims window | Pineles et al., *Ophthalmic Epidemiology* citeturn22search2turn22search5 | **[Measured]** | The claims signal strongly suggests differential diagnosis or access patterns, not only disease biology. |
| **10.6% vs 7.4% vs 5.9% vs 5.3%** | Any significant eye diagnosis by region | Northeast vs Midwest vs South vs West in OptumLabs claims | 2010–2018 claims window | Pineles et al., *Ophthalmic Epidemiology* citeturn22search2turn22search5 | **[Measured]** | The regional gradient is probably telling us as much about access and detection as about underlying disease. |
| **174,000 children** | Number of visually impaired children ages 3–5 | United States, all races/ethnicities | 2015 | Varma et al., *JAMA Ophthalmology* 2017 citeturn25search26turn29search6 | **[Modeled]** | This is the downstream, already-harmed subgroup, not the full at-risk pool. |
| **121,000 children** | Visual impairment due to simple uncorrected refractive error | U.S. children ages 3–5 with visual impairment | 2015 | Varma et al., *JAMA Ophthalmology* 2017 citeturn25search26turn29search6 | **[Modeled]** | Most preschool visual impairment in this model was from a potentially correctable cause. |
| **43,000 children** | Visual impairment due to bilateral amblyopia | U.S. children ages 3–5 with visual impairment | 2015 | Varma et al., *JAMA Ophthalmology* 2017 citeturn25search26turn29search6 | **[Modeled]** | Bilateral amblyopia is a smaller but still substantial contributor to serious preschool vision loss. |
| **220,600 children** | Projected number of visually impaired children ages 3–5 | United States | 2060 projection | Varma et al., *JAMA Ophthalmology* 2017 citeturn29search1turn29search6 | **[Modeled]** | The modeled burden rises even without assuming worsening prevalence, because the child population mix changes over time. |
| **+26%** | Projected increase in preschool visual impairment | U.S. children ages 3–5 | 2015 to 2060 | Varma et al., *JAMA Ophthalmology* 2017 citeturn25search26turn29search1 | **[Modeled]** | Forward burden is not flat; the system must plan for growth. |
| **Method: pooled age/race prevalence × U.S. Census projections** | Projection method | Preschool visual impairment model | 2015–2060 | Varma et al., *JAMA Ophthalmology* 2017 and PMC text citeturn29search1turn31search1 | **[Modeled]** | This is exactly the kind of multiplier model the user asked to see identified explicitly. |
| **61%** | Vision screening within the last 2 years | U.S. school-age children ages 6 to <18, NSCH | 2021 | Oke et al., *JAMA Ophthalmology* 2024 citeturn18search2 | **[Measured]** | Nearly 4 in 10 school-age children still missed this screening window. |
| **30%** | Referred for eye examination after screening | Among screened U.S. school-age children, NSCH | 2021 | Oke et al., *JAMA Ophthalmology* 2024 citeturn18search2 | **[Measured]** | Screening generates a large specialist workload downstream. |
| **92%** | Established specialty care after referral | Among referred U.S. school-age children, NSCH | 2021 | Oke et al., *JAMA Ophthalmology* 2024 citeturn18search2 | **[Measured]** | Once referred in this survey pathway, most school-age children reportedly reached specialty care. |
| **≈ 16.8% of all school-age children** | Reached specialty care via the screening pathway | 61% screened × 30% referred × 92% established care | 2021 pathway applied arithmetically | Author calculation from NSCH pathway results citeturn18search2 | **[Estimate]** | This is the practical throughput from “all school-age kids” to “screened, referred, then seen.” |
| **Screening at age 3: ~40%** | Primary-care screening rate | U.S. children age 3 | USPSTF evidence summary cited 2017 | USPSTF recommendation statement citeturn12search15turn27search17 | **[Measured]** | The pipeline starts narrow in the exact ages where amblyopia treatment sensitivity matters most. |
| **55.0%** | Received vision screening from a non-eye-doctor provider | U.S. children 0–5 ever / 6–17 within past 2 years, combined NSCH estimate | 2022–2023 combined | NSCH Data Resource Center citeturn13search9 | **[Measured]** | Different screening questions give different percentages; definitions matter. |
| **59%** | Completed follow-up exam after preschool referral | Preschoolers referred after failed screening, community-based follow-up program baseline | Study published 2016 | Lowry et al., *JAMA Ophthalmology* 2016 citeturn16search0turn16search14 | **[Measured]** | Follow-up failure remains one of the biggest losses in the preschool funnel. |
| **50.5% to 63.8%** | Follow-up rate range used in threshold/cost modeling | Preschool referral follow-up scenarios | Study published 2016 | Lowry et al., *JAMA Ophthalmology* 2016 citeturn16search0 | **[Modeled]** | Even the “good” end of realistic follow-up assumptions still leaves a lot of children not reaching a full exam. |
| **73% threshold** | Mobile follow-up becomes equally cost-effective vs community follow-up | Preschool referral programs | Study published 2016 | Lowry et al., *JAMA Ophthalmology* 2016 citeturn16search0turn27search4 | **[Modeled]** | Better follow-up can justify more intensive delivery models, but the threshold is not trivial. |
| **5.7% → 72.1%** | Age-3 screening rate after photoscreener expansion | Multispecialty Northern California practice, 57,527 3-year-olds | 2015 to 2022 | Stults et al., *JAMA Ophthalmology* 2024 citeturn35search1turn36search1 | **[Measured]** | Screening coverage can be transformed rapidly when systems actually deploy photoscreening broadly. |
| **17.0% → 23.6% → 15.7%** | Referral rate in same age-3 cohort | Same practice-based cohort | 2015, peak 2018, 2022 | Stults et al. summaries citeturn36search3turn36search9 | **[Measured]** | More screening does not automatically mean proportionally more referrals forever; referral behavior changes with implementation and case mix. |
| **2.7% → 3.4% → 1.4%** | Amblyopia diagnosis rate in same age-3 cohort | Same practice-based cohort | 2015, peak 2018, 2022 | Stults et al., PubMed/JAMA summary citeturn36search0turn36search3 | **[Measured]** | Diagnosis rate fell after the early rise, which may reflect earlier detection, changing criteria, or broader screening of lower-risk children. |
| **4.2% to 17.6%** | Reported prevalence range for convergence insufficiency in children | Literature synthesis, not a national U.S. prevalence study | Review cited 2021 | Alvarez et al., *Scientific Reports* 2021 citeturn9search14turn30search19 | **[Low-confidence]** | CI is common enough to matter clinically, but U.S. national population-based prevalence is still weak. |
| **3.4% to 7.7%** | Reported prevalence range for convergence insufficiency in adults | Literature synthesis, not a national U.S. prevalence study | Review cited 2021 | Alvarez et al., *Scientific Reports* 2021 citeturn9search14turn30search19 | **[Low-confidence]** | Adult binocular dysfunction burden is probably substantial, but current U.S. estimates are not clean enough for a high-confidence national count. |
| **8.44 per 100,000 adults/year** | Adult-onset convergence insufficiency incidence | Population-based adult cohort in Olmsted County, Minnesota | Article 2015 | Ghadban et al., PubMed/PMC citeturn25search4turn30search3 | **[Measured]** | CI is one of the major adult-onset strabismus categories orthoptists see, but incidence is still modest compared with general refractive care volumes. |
| **≈ 22,645 new adult cases/year** | Estimated annual new adult-onset CI cases | U.S. adults, using 8.44/100,000 × adult population | 2025 denominator | Author calculation from Census 2025 + Olmsted incidence citeturn23search2turn25search4 | **[Estimate]** | Even with a modest incidence rate, this still produces a national annual case volume in the tens of thousands. |
| **54.1 per 100,000 adults/year** | Adult-onset strabismus incidence | Population-based adult cohort in Olmsted County, Minnesota | Article 2013/2014 | Martinez-Thompson et al., PMC/PubMed citeturn30search12turn25search7 | **[Measured]** | Adult strabismus is not niche; incident burden accumulates quickly in a large adult population. |
| **1 in 25 adults** | Lifetime risk of diagnosis with adult-onset strabismus | Same Olmsted adult cohort | Article 2013/2014 | Martinez-Thompson et al. citeturn30search12turn25search7 | **[Measured]** | This is one of the clearest reminders that orthoptic-type disorders are not just pediatric. |
| **≈ 145,151 new adult cases/year** | Estimated annual new adult-onset strabismus cases | U.S. adults, using 54.1/100,000 × adult population | 2025 denominator | Author calculation from Census 2025 + Olmsted incidence citeturn23search2turn30search12 | **[Estimate]** | National adult strabismus incidence is likely in the six-figure range annually. |
| **850,000 visits/year** | Diplopia-related ambulatory + ED visits | United States, all ages; visit count, not patient count | 2003–2012 nationally representative visit data; article 2017 | De Lott et al., *JAMA Ophthalmology* 2017 citeturn30search1turn8search4 | **[Measured]** | Diplopia is one of the clearest adult orthoptic-service demand signals because the national unit is actual visits. |
| **95%** | Share of diplopia visits that were outpatient | United States, all ages | 2003–2012 nationally representative visit data | De Lott et al., *JAMA Ophthalmology* 2017 citeturn30search1turn30search13 | **[Measured]** | Most diplopia care load is ambulatory, not emergency. |
| **6.72 per 100,000 children/year** | Pediatric nystagmus incidence | Children <19 years, population-based North American cohort | Article 2017 | Nash et al., PubMed/AAO EyeNet citeturn25search23turn30search22 | **[Measured]** | Pediatric nystagmus is uncommon, but at national scale it still generates thousands of new cases annually. |
| **≈ 4,938 new pediatric cases/year** | Estimated annual new pediatric nystagmus cases | U.S. children under 18, using 6.72/100,000 × child population | 2025 denominator | Author calculation from Census 2025 + Nash incidence citeturn23search2turn25search23 | **[Estimate]** | Rare conditions stop being “small” once you multiply them by the U.S. pediatric population. |
| **4.65 per 100,000 adults/year** | Adult-onset central nystagmus incidence | Adults, population-based cohort in Olmsted County | Article 2025 | Rattanathamsakul et al., PubMed citeturn32search2 | **[Measured]** | Adult acquired nystagmus is uncommon but not negligible, especially in neuro-ophthalmic practice. |
| **≈ 12,476 new adult cases/year** | Estimated annual new adult central nystagmus cases | U.S. adults, using 4.65/100,000 × adult population | 2025 denominator | Author calculation from Census 2025 + Olmsted adult incidence citeturn23search2turn32search2 | **[Estimate]** | National adult neuro-orthoptic burden from nystagmus alone is likely in the low tens of thousands yearly. |
| **24 per 10,000 overall; 17 per 10,000 pediatric; 26.5 per 10,000 adult** | Pathologic nystagmus prevalence | General population, outside the U.S. | Older epidemiologic survey | Sarvananthan et al., via EyeWiki/clinical summaries citeturn31search17turn32search4 | **[Low-confidence]** | These are useful comparators because U.S. prevalence data are thin, but they are not U.S. national estimates. |
| **73%** | Successful-or-improved outcome after 12 weeks of office-based therapy with home reinforcement | Children 9–17 with symptomatic convergence insufficiency | Trial published 2008 | CITT randomized trial summaries citeturn33search1turn33search0 | **[Measured]** | For properly diagnosed CI, treatment efficacy is strong when the right modality is used. |
| **43%, 33%, 35%** | Successful-or-improved outcome for home pencil push-ups, home computer therapy + push-ups, and office placebo | Same CI trial | Trial published 2008 | CITT randomized trial summaries citeturn33search1 | **[Measured]** | The treatment modality matters a lot; “therapy” is not one undifferentiated thing. |
| **87.5%** | Still successful or improved 1 year later after office-based therapy | Children who were asymptomatic after initial 12-week CI therapy | Article 2009 | Long-term CITT follow-up citeturn10search3turn33search5 | **[Measured]** | Gains in CI can stick, which matters for long-term orthoptic value. |
| **53% vs 25%** | Responder rate with active amblyopia treatment vs optical correction alone | Children 7 to <13 years with amblyopia | PEDIG trial published 2005 | Scheiman et al., PubMed/PEDIG public summary citeturn10search1turn10search16 | **[Measured]** | Older children are still treatable, but the response is worse than in younger children and still incomplete. |
| **About 1 in 5** | Achieved 20/25 or better after atropine or patching | Children 7–12 years with moderate amblyopia | Article 2008 | PEDIG trial summary citeturn10search10turn10search0 | **[Measured]** | Treatment works, but “full normalization” is not the most common outcome in later-treated moderate amblyopia. |
| **Similar improvement by 6 months** | Atropine vs patching for moderate amblyopia in children <7 | Children younger than 7 years | Trial published 2002 | PEDIG ATS-1 / NEI summary citeturn10search8turn10search19 | **[Measured]** | This underpins why orthoptic/pediatric ophthalmology practice does not rely on one single amblyopia modality. |
| **Atropine better tolerated than patching** | Acceptability/compliance burden | Children in amblyopia treatment trial | Article 2003 and NEI summary | Holmes et al.; NEI summary citeturn11search18turn10search19 | **[Measured]** | The adherence bottleneck is partly social and behavioral, not just clinical. |
| **71%** | Consistent eyeglass wear during first year | Preschoolers from low-income families in San Francisco with prescribed glasses | 2017–2018 school year; article 2021 | Sabharwal et al., *JAMA Ophthalmology* 2021 citeturn37search0turn37search11 | **[Measured]** | Once glasses are prescribed, real-world adherence is far from perfect but better than many clinicians assume. |
| **< 50%** | Typical patching adherence reported in studies | Children undergoing amblyopia patching | Review/technology paper 2022 | Ahmad et al., 2022 review summary citeturn37search12 | **[Low-confidence]** | Patching failure often reflects implementation failure as much as biological nonresponse. |
| **80% vs 34%** | Measured compliance in children with satisfactory vs unsatisfactory acuity improvement | Electronically monitored amblyopia patching study | Older clinical study | Awan et al./electronic monitoring summary citeturn37search15 | **[Measured]** | Better adherence tracks with better vision gain, exactly what clinicians expect but now with objective monitoring. |
| **≈ 25%** | Recurrence after successful amblyopia treatment | Children in PEDIG-era recurrence studies | 1-year follow-up after stopping treatment | Holmes et al.; AAO summary citeturn11search6turn11search9 | **[Measured]** | “Resolved” is not always permanent; follow-up matters. |
| **OR 0.41** | Odds of getting an appointment for children with Medicaid vs BCBS | Simulated access study in Michigan and Maryland eye care practices | Article 2018 | Lee et al., *JAMA Ophthalmology* citeturn40search1turn40search2 | **[Measured]** | Insurance status is a real point-of-entry barrier before the clinic encounter even begins. |
| **OR 8.00** | Better odds of appointment with optometrist versus ophthalmologist for children with Medicaid | Same access study | Article 2018 | Lee et al., *JAMA Ophthalmology* citeturn40search17 | **[Measured]** | Access patterns depend strongly on practitioner type, which directly affects how orthoptic and pediatric ophthalmology demand is routed. |
| **46 days vs 14 days** | Median appointment wait time for Medicaid vs private insurance | North Carolina practice survey | Article 2026 | Duke Scholars repository / *J AAPOS* article record citeturn40search12 | **[Measured]** | Wait time is another hidden attrition point in the funnel. |
| **56% vs 100%** | Practices offering routine eye care to Medicaid children ages 0–5 vs 6–17 | North Carolina Medicaid-participating practices | Article 2026 | Duke Scholars repository / *J AAPOS* article record citeturn40search12 | **[Measured]** | The youngest Medicaid children face the tightest supply constraint, which is exactly the wrong age to miss amblyopia-sensitive care. |
| **20%** | Medicaid-participating practices that did not provide Medicaid-covered spectacles | North Carolina practice survey | Article 2026 | Duke Scholars repository / *J AAPOS* article record citeturn40search12 | **[Measured]** | Even after you get through diagnosis, obtaining the actual treatment device can still fail. |
| **9.7% of counties** | Counties with at least one pediatric ophthalmologist | U.S. counties | 2023 | Siegler et al., *JAMA Ophthalmology* 2024 citeturn38search0turn38search2 | **[Measured]** | Pediatric eye care is geographically sparse. |
| **6.5% of counties** | Counties with at least one pediatric optometrist | U.S. counties | 2023 | Siegler et al., *JAMA Ophthalmology* 2024 citeturn38search0turn38search2 | **[Measured]** | Alternative pediatric eye-care pathways are sparse too; shortages overlap rather than compensate. |
| **96.4%** | Counties lacking both pediatric ophthalmologists and pediatric optometrists among those without a pediatric ophthalmologist | U.S. counties | 2023 | Siegler et al., *JAMA Ophthalmology* 2024 citeturn38search0 | **[Measured]** | Geographic access deserts remain a structural bottleneck in the orthoptics-relevant care pathway. |
| **$5.7 billion** | Economic burden of pediatric vision/eye problems | U.S. children birth to 17 years | 2013 dollars | APHA policy brief citing Prevent Blindness economic work citeturn28search16 | **[Estimate]** | Even the conservative pediatric-only economic burden is already very large. |
| **$10 billion yearly** | Economic cost of children’s vision disorders, including broader burdens/QOL | United States | Reported circa 2019 | Prevent Blindness national priority summary citeturn28search5 | **[Estimate]** | This higher figure likely includes broader quality-of-life and caregiver costs, explaining why it exceeds the $5.7B estimate. |
| **45%** | Share of children’s vision-disorder costs borne by families | United States | Reported circa 2019 | Prevent Blindness national priority summary citeturn28search5 | **[Estimate]** | Family-level financial burden is not incidental; it is nearly half the total in this estimate. |
| **1.2% lifetime risk** | Projected lifetime risk of vision loss in people with amblyopia after loss/disease in the better eye | Adults with amblyopia | Population-risk literature | Rahi et al., *Lancet* 2002 / van Leeuwen et al. / Nilsson commentary citeturn27search11turn27search15turn27search19 | **[Measured]** | This is the classic argument that amblyopia is not “just one weaker eye” but a lifelong two-eye risk problem. |
| **Untreated amblyopia almost doubles lifetime risk of bilateral visual impairment** | Comparative risk framing | Population-risk literature | Commentary 2007 | Nilsson et al., *Br J Ophthalmol* 2007 citeturn27search2turn27search19 | **[Measured]** | It is a concise way of explaining why early orthoptic and pediatric-ophthalmic care has high lifetime value. |
| **$22,000 to $75,000 per QALY willingness-to-pay band** | Range in which preschool + kindergarten acuity/stereopsis screening was most cost-effective | Amblyopia screening model | Article 2011 | Rein et al., *Arch Ophthalmol* 2011 citeturn27search14turn27search29 | **[Modeled]** | Screening programs are economically defensible under mainstream cost-effectiveness thresholds. |
| **> $75,000 per QALY willingness-to-pay** | Range where preschool photoscreening + kindergarten acuity/stereopsis became most cost-effective | Amblyopia screening model | Article 2011 | Rein et al., *Arch Ophthalmol* 2011 citeturn27search14 | **[Modeled]** | More intensive preschool screening can be justified when society places higher value on avoiding monocular loss. |

## Treatment funnel

No single national U.S. dataset follows the same child from **screening → referral → follow-up exam → diagnosis → treatment initiation → adherence → resolution** for amblyopia/strabismus/anisometropia. The cleanest way to stay honest is to show the pathway in pieces, label the population for each piece, and avoid pretending the percentages come from one cohort. citeturn18search2turn16search0turn35search0turn16search5

### School-age pathway with nationally representative linkage

| Stage | % retained | Source | Year | Confidence |
|---|---:|---|---:|---|
| Screened within prior 2 years | **61%** of all U.S. school-age children | NSCH analysis, Oke et al. citeturn18search2 | 2021 | **[Measured]** |
| Referred for eye examination after screening | **30%** of screened children | NSCH analysis, Oke et al. citeturn18search2 | 2021 | **[Measured]** |
| Established specialty care after referral | **92%** of referred children | NSCH analysis, Oke et al. citeturn18search2 | 2021 | **[Measured]** |
| Net through-put to “screened + referred + seen” | **16.8%** of all school-age children | Author arithmetic: 0.61 × 0.30 × 0.92 citeturn18search2 | 2021 | **[Estimate]** |

### Preschool amblyopia-risk pathway with assembled stage estimates

| Stage | % retained | Source | Year | Confidence |
|---|---:|---|---:|---|
| Screened at age 3 | **~40%** | USPSTF recommendation statement evidence summary citeturn12search15turn27search17 | 2017 evidence base | **[Measured]** |
| Amblyopia risk factors / positive yield | **5.0%** of preschoolers screened in 16 U.S. photoscreening programs | USPSTF evidence review citeturn34search0turn34search6 | 2017 review | **[Measured]** |
| Referred after systemwide age-3 screening | **15.7% to 23.6%** | Northern California practice cohort with photoscreener rollout citeturn36search3turn36search9 | 2015–2022 | **[Measured]** |
| Completed follow-up eye exam after referral | **~59%** baseline; modeled range **50.5% to 63.8%** | Lowry et al., preschool referral follow-up study citeturn16search0turn16search14 | 2016 | **[Measured] / [Modeled]** |
| Amblyopia diagnosis in age-3 screening cohort | **1.4% to 3.4%** of all 3-year-olds in the practice cohort | Stults et al. citeturn36search0turn36search3 | 2015–2022 | **[Measured]** |
| Consistent spectacle adherence once glasses prescribed | **71%** | San Francisco preschoolers from low-income families citeturn37search0turn37search11 | 2017–2018 school year / article 2021 | **[Measured]** |
| Patching adherence in the literature | Often **<50%** | Review/technology summary citeturn37search12 | 2022 summary | **[Low-confidence]** |
| Vision response in older children with amblyopia | **53% responded** with active treatment vs **25%** with optical correction alone | PEDIG trial citeturn10search1turn10search16 | 2005 | **[Measured]** |
| Full-ish resolution benchmark | About **1 in 5** reached 20/25 or better with atropine or patching in 7–12 year olds | PEDIG trial citeturn10search10turn10search0 | 2008 | **[Measured]** |
| Recurrence after successful amblyopia treatment | **~25%** within 1 year | PEDIG-era recurrence evidence citeturn11search6turn11search9 | 2004 onward | **[Measured]** |

The practical interpretation is blunt: the biggest drop-offs are **before diagnosis**. Once a child is actually in pediatric ophthalmology/orthoptic care and adheres reasonably well, improvement is common; the weak link is getting enough children into that channel early enough. citeturn16search0turn18search2turn10search8turn33search1

## What the numbers mean together

If you zoom out from any single condition, the U.S. picture is dominated by a three-layer structure. The first layer is the **large upstream pool of amblyopia risk**: about **5% of preschool children** screen as having amblyopia risk factors, and about **5.1%** in BPEDS would have met prescribing criteria for spectacle correction, while only **1.3%** had already been prescribed correction. That means there is a very large population of children who are not yet necessarily amblyopic or strabismic in claims, but who sit in the exact risk zone where orthoptists, pediatric ophthalmologists, and screening programs can still change the trajectory. citeturn34search0turn7search10turn7search22

The second layer is the **established pediatric burden**. Preschool-strabismus prevalence around **2.5% to 2.6%** and amblyopia around **~2%** do not sound huge until you multiply them by the U.S. child denominator. At that point, these become problems measured in **hundreds of thousands of preschool children** and probably **millions of diagnosed children** once the age range extends to all of childhood. Claims-based data reinforce that view: strabismus is the most common major pediatric eye diagnosis in a large U.S. commercial database, and amblyopia remains a major second-tier diagnosed condition. citeturn31search8turn31view3turn22search1turn22search2

The third layer is the **adult orthoptic burden**, which is easier to underestimate because it is dispersed across adult strabismus, diplopia, convergence insufficiency, and neuro-ophthalmic nystagmus rather than concentrated in one preschool screening program. Population-based incidence work from Olmsted County suggests that adult-onset strabismus is common enough to generate on the order of **145,000 new U.S. cases per year** if applied nationally, while diplopia already surfaces directly as about **850,000 ambulatory and ED visits annually**. That is not an optometry-style refractive-care burden; it is exactly the kind of motility/binocular-vision/neuro-ophthalmic burden orthoptists are built to help manage. citeturn30search12turn30search1turn25search4turn32search2turn23search2

The hardest part of the U.S. story is not proving that treatment can work. The PEDIG amblyopia trials and the CITT convergence-insufficiency trials already did that. The hard part is proving that the health system reliably gets the right child from “screened” to “treated before the sensitive period closes.” The available evidence says it often does not. Depending on the dataset and age group, the system loses children at screening coverage, at referral completion, at appointment access, at spectacle coverage, and again at adherence. That is why the U.S. evidence base feels fragmented: it is fragmented because the actual care pathway is fragmented. citeturn27search17turn16search0turn40search1turn40search12turn10search8turn33search1

## Disparities and access barriers

The disparity pattern is consistent across screening, diagnosis, and access. In the 2021 NSCH analysis of pediatric vision screening and eye care, disadvantaged children were less likely to receive screening and regular eye care; lower rates were associated with younger age, lack of insurance coverage, and household languages other than English, while lower income and lower parental education also tracked with lower screening odds. In the school-age NSCH pathway analysis, the authors concluded that children from historically vulnerable groups were less likely to receive screening and specialty care. citeturn21search4turn21search5turn18search2turn21search1

Claims-based and health-system data point the same way. In OptumLabs, the prevalence of any significant pediatric eye diagnosis was **6.9% in White children**, **5.6% in Black children**, and **5.9% in Hispanic children**, while diagnosed disease was also much higher in the Northeast than in the West. The most plausible interpretation is not that children in the Northeast are biologically twice as sick, but that detection, access, and utilization vary by region and population. Pineles and colleagues themselves explicitly note that under-utilization and under-diagnosis outside better-served populations are likely explanations for at least part of the gradient. citeturn22search2turn22search5

Insurance is one of the sharpest barriers. In a simulated appointment-access study in Michigan and Maryland, children with Medicaid had **0.41 times the odds** of obtaining an appointment compared with children with Blue Cross Blue Shield, while appointment odds were much better with optometrists than ophthalmologists in that experiment. A newer North Carolina practice survey found that among Medicaid-participating practices, only **56%** offered routine eye care to children ages 0–5, compared with **100%** for ages 6–17; median waits were **46 days for Medicaid** versus **14 days** for privately insured children seen at non-Medicaid practices; and **20%** of Medicaid-participating practices did not provide Medicaid-covered spectacles. That is a textbook example of why the preschool amblyopia funnel leaks hardest in the children who most need early care. citeturn40search1turn40search17turn40search12

Geography compounds the insurance problem. In 2023, only **9.7% of U.S. counties** had at least one pediatric ophthalmologist and only **6.5%** had at least one pediatric optometrist; among counties without a pediatric ophthalmologist, **96.4%** also lacked a pediatric optometrist. The overlap matters: one workforce is not filling the other’s gaps. Low-socioeconomic-status regions were the most likely to lack both kinds of pediatric eye-care practitioners, which means the screening funnel is often feeding into literal access deserts. citeturn38search0turn38search2

## Economic and human burden

There are two ways to value the burden, and they produce different numbers for a reason. A conservative pediatric-only estimate cited by APHA put the economic burden of pediatric vision and eye problems at **$5.7 billion** in 2013 for U.S. children from birth to age 17. Prevent Blindness has also circulated a broader figure of about **$10 billion yearly** for children’s vision disorders and says families shoulder about **45%** of those costs. Those numbers are not necessarily contradictory: the higher figure appears to include broader quality-of-life and caregiver burdens, while the lower figure is more conservative about what gets monetized. citeturn28search16turn28search5

For amblyopia specifically, the classic long-run burden is not just reduced acuity in one eye. The “second eye” literature estimated the projected lifetime risk of vision loss for a person with amblyopia at **at least 1.2%** if disease or injury later affects the better eye, and later commentary summarized untreated amblyopia as **nearly doubling the lifetime risk of bilateral visual impairment**. In other words, early treatment is not merely cosmetic or school-performance optimization; it is risk reduction against a lifelong two-eye portfolio problem. citeturn27search11turn27search15turn27search19

The human burden of strabismus also goes well beyond acuity. Parent-proxy data in preschoolers show worse general health-related quality of life for children with strabismus, and a 2021 review concluded that strabismus has meaningful psychosocial effects in both children and adults. That matters for orthoptics because the specialty’s value is not just “reduce prism diopters.” It is also about reducing diplopia, improving binocular function, helping children use glasses and patching successfully, and improving the psychosocial experience of visible ocular misalignment. citeturn27search12turn27search28

On cost-effectiveness, the evidence is favorable but conditional on assumptions. Rein and colleagues found that amblyopia screening strategies were cost-effective over common willingness-to-pay ranges: **preschool plus kindergarten acuity/stereopsis screening** was most cost-effective at **$22,000 to $75,000 per QALY**, while **preschool photoscreening plus kindergarten acuity/stereopsis** became most cost-effective above **$75,000 per QALY**. Lowry’s preschool follow-up study adds the operational twist: community follow-up was more cost-effective than mobile follow-up in **88%** of modeled scenarios, but mobile follow-up became equally cost-effective when follow-up rose to about **73%**. The implication is straightforward: the economics improve when programs solve the follow-up problem rather than merely generating referrals. citeturn27search14turn27search29turn27search4turn16search0

## Data gaps

The evidence is good enough to show that orthoptics-relevant disease burden is large, disparities are real, and early treatment works. It is **not** good enough to answer several key U.S. questions cleanly.

- There is still **no national linked dataset** that follows the same child from screening to referral to eye exam to diagnosis to treatment start to adherence to final visual outcome. Most “funnels” have to be assembled from separate studies. citeturn18search2turn16search0turn16search5
- **Condition-specific national prevalence for anisometropia, amblyogenic refractive error, convergence insufficiency, accommodative dysfunction, and nystagmus** remains thin compared with amblyopia and strabismus, especially in modern U.S. population-based datasets. citeturn34search0turn9search14turn31search17
- National evidence on **treatment initiation rates** after diagnosis is weak. We have much better evidence for treatment efficacy than for how often diagnosed children actually start glasses, patching, atropine, prisms, therapy, or surgery in routine U.S. care. citeturn10search8turn33search1turn35search15
- National evidence on **real-world adherence** is also fragmented. Spectacle wear, patching adherence, and atropine adherence are usually measured in local cohorts or trials, not in national routine-care datasets. citeturn37search0turn37search12turn11search3
- Forward U.S. projections are much better for **preschool visual impairment** than for the specific orthoptic diagnoses themselves. There is no equally strong recent U.S. forecast to 2030 or 2050 for strabismus, amblyopia, anisometropia, or CI as stand-alone conditions. citeturn29search1turn29search6
- Disparity evidence is strong for insurance, income, language, and geography, but still not strong enough to show **exact national drop-off percentages by race/ethnicity or rurality at every stage** of the funnel. citeturn21search5turn38search0turn40search12